Henry Schein (HSIC) AI Stock Analysis

• Market Cap: $8.68B
• Dividend Yield: N/A
• Average Volume (3M): 1.43M
• Price to Earnings (P/E): 22.6
• Beta (1Y): 0.35
• Revenue Growth: 3.51%
• EPS Growth: 29.65%
• Country: US
• Employees: 25,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 1.38
• Shares Outstanding: 121,268,394
• 10 Day Avg. Volume: 1,743,400
• 30 Day Avg. Volume: 1,434,129
• PEG Ratio: -7.28
• Price to Book (P/B): 2.63
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 13.51
• Enterprise Value/Market Cap: 1.48
• Enterprise Value/Revenue: 1.32
• Enterprise Value/Gross Profit: 4.41
• Enterprise Value/Ebitda: 17.35
• 1Y Price Target: $74.50
• Price Target Upside: 3.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: $74.00 ▲(2.76% Upside)

Henry Schein's overall stock score reflects a stable financial position with strong strategic initiatives and sales growth highlighted in the earnings call. The technical indicators suggest a bullish trend, though caution is advised due to overbought signals. The valuation is moderate, and the absence of a dividend yield may be a drawback for some investors.

Positive Factors

Strong Sales Growth

Consistent sales growth across all segments indicates robust demand and effective market strategies, supporting long-term revenue expansion.

BOLD+1 Strategy Success

The successful execution of strategic initiatives like BOLD+1 enhances operational efficiency and profitability, laying a strong foundation for future growth.

Growth in Technology Solutions

Significant growth in technology solutions, particularly cloud-based services, positions the company well in the digital transformation of healthcare.

Negative Factors

Cash Flow Challenges

Declining free cash flow growth can hinder the company's ability to invest in new opportunities and manage debt, affecting long-term financial health.

Low Net Profit Margin

A low net profit margin indicates potential inefficiencies in cost management, which could impact profitability and competitiveness over time.

Decline in Dental Equipment Sales

Sluggish growth in dental equipment sales may signal market saturation or competitive pressures, affecting future revenue potential in this segment.

Henry Schein Business Overview & Revenue Model

Company Description

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

How the Company Makes Money

Henry Schein generates revenue through several key streams, primarily by distributing a diverse range of healthcare products and services to practitioners in the dental, medical, and veterinary fields. The company earns income from the sale of consumable products, including supplies and equipment, as well as through its technology solutions, which encompass software for practice management and digital imaging. Additionally, Henry Schein benefits from value-added services such as inventory management, consulting, and training. Significant partnerships with manufacturers and suppliers enable the company to maintain a robust supply chain and competitive pricing. The company's revenue model is further supported by its extensive customer base and strong market presence across various healthcare sectors, allowing it to capitalize on ongoing demand for healthcare products and services.

Henry Schein Financial Statement Overview

Summary

Henry Schein demonstrates a stable financial position with consistent revenue and profit margins. The balance sheet is solid with manageable leverage, but there is a need to enhance cash flow generation. The company should focus on improving operational efficiency and cash flow management to strengthen its financial health further.

Income Statement

Henry Schein's income statement shows a stable revenue base with a slight growth in the TTM period. The gross profit margin is healthy at 31.1%, indicating efficient cost management. However, the net profit margin is relatively low at 3.2%, suggesting room for improvement in operational efficiency. The EBIT and EBITDA margins are moderate, reflecting stable operational performance but with potential for enhanced profitability.

Balance Sheet

The balance sheet reveals a balanced financial structure with a debt-to-equity ratio of 0.97, indicating manageable leverage. The return on equity is reasonable at 11.9%, showing effective use of equity capital. The equity ratio stands at 31.6%, suggesting a solid equity base relative to total assets, though there is room for strengthening equity further.

Cash Flow

Cash flow analysis indicates challenges with a significant decline in free cash flow growth. The operating cash flow to net income ratio is low at 0.24, highlighting potential cash generation issues. The free cash flow to net income ratio is decent at 0.75, but the negative growth trend in free cash flow is a concern that needs addressing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2019	Dec 2018
Income Statement
Total Revenue	9.75B	12.67B	12.34B	12.65B	9.99B	13.20B
Gross Profit	2.91B	4.02B	3.86B	3.83B	3.09B	3.60B
EBITDA	740.00M	941.00M	877.00M	1.08B	917.91M	837.10M
Net Income	297.00M	390.00M	416.00M	538.00M	719.14M	535.88M
Balance Sheet
Total Assets	11.10B	10.22B	10.57B	8.61B	7.15B	8.50B
Cash, Cash Equivalents and Short-Term Investments	136.00M	122.00M	171.00M	117.00M	106.10M	80.21M
Total Debt	3.44B	2.87B	2.74B	1.50B	998.35M	1.96B
Total Liabilities	6.20B	5.38B	5.42B	3.94B	3.23B	4.96B
Stockholders Equity	3.36B	3.39B	3.65B	3.45B	3.00B	2.96B
Cash Flow
Free Cash Flow	223.00M	661.00M	313.00M	506.00M	577.87M	594.07M
Operating Cash Flow	331.00M	848.00M	500.00M	602.00M	654.09M	684.71M
Investing Cash Flow	-259.00M	-430.00M	-1.14B	-276.00M	-424.37M	-192.95M
Financing Cash Flow	24.00M	-510.00M	701.00M	-315.00M	-215.98M	-603.78M

Henry Schein Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 72.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSIC, the sentiment is Positive. The current price of 72.01 is above the 20-day moving average (MA) of 64.25, above the 50-day MA of 66.22, and above the 200-day MA of 69.77, indicating a bullish trend. The MACD of 0.54 indicates Negative momentum. The RSI at 74.08 is Negative, neither overbought nor oversold. The STOCH value of 87.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HSIC.

Henry Schein Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COR	76 Outperform	$66.80B	35.44	130.60%	0.62%	11.56%	5.31%
MCK	70 Outperform	$104.69B	33.58	―	0.36%	20.35%	11.96%
HSIC	69 Neutral	$8.68B	22.59	11.39%	―	3.51%	29.65%
CAH	65 Neutral	$46.41B	29.49	―	1.04%	4.37%	28.48%
PBH	62 Neutral	$2.98B	14.20	12.05%	―	0.63%	4.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMI	40 Underperform	$269.94M	―	-184.47%	―	-37.09%	-2639.44%

Henry Schein Corporate Events

Henry Schein Reports Strong Q3 2025 Earnings

Henry Schein, Inc., a leading provider of healthcare solutions for dental and medical practitioners, has reported its financial results for the third quarter of 2025, showcasing a strong performance across its business segments. The company, which operates in the healthcare sector, is renowned for its comprehensive solutions that enhance operational success and clinical outcomes for over a million customers worldwide.

Henry Schein’s Earnings Call Highlights Growth and Challenges

The recent earnings call for Henry Schein painted a picture of balanced sentiment, showcasing robust sales growth and strategic initiatives that are gaining traction. However, the company also faces challenges, particularly in the dental equipment segment where growth has been slower, and mixed product demand is impacting margins.

Henry Schein’s Senior Advisor James Breslawski Departs

James Breslawski, who transitioned from President to Senior Advisor at Henry Schein, Inc. on April 1, 2025, has now left his advisory role as of September 5, 2025. Following his departure, he will receive payments and benefits as per the company’s Executive Severance Plan.

The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.